What GLP-1 Does Kaiser Cover? 8 Kaiser Documents for 2026

Affiliate disclosure: The RX Index may earn a commission from some links on this page. It does not change which Kaiser documents we read, what we found in them, or the order we present the evidence. The RX Index is not affiliated with Kaiser Permanente and Kaiser does not pay us.

What GLP-1 does Kaiser cover? There is no one Kaiser answer. Across the eight exact 2026 plan documents and approval-criteria sets we opened, Ozempic appeared in all eight, while a liraglutide product or approval path appeared in seven. Wegovy, Zepbound, Mounjaro, Rybelsus, Wegovy tablets, and Foundayo changed a lot by market, plan, product form, and reason for treatment. And here is the part that trips everyone up: being on the list is not the same as being covered.

That last sentence is the whole page. A Kaiser plan document can print Zepbound at Tier 3 and say near the front that most plans exclude weight-loss drugs. Both are true at the same time. If you don't know why, you can spend six months filing the wrong form.

We're going to show you exactly which document says what, when it took effect, and which of five questions decides your answer.

Is this page for you?

This page is for you if:

• You have a Kaiser card and want to know what it actually pays for
• You were told "we don't cover that" and nobody explained why
• You got denied and can't tell if it's a paperwork problem or a benefit problem
• You're picking a plan at open enrollment and GLP-1s matter to you

This page is not for you if:

• You want us to promise what your exact plan will pay. Nobody can do that from the outside, and we'll show you why in about two minutes.
• You're shopping for compounded semaglutide. We did not find a compounded-semaglutide coverage path in the Kaiser documents we reviewed, and we keep FDA-approved and compounded medications strictly separate.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

The 30-second answer

Does Kaiser cover GLP-1 drugs for weight loss? First, know the two questions

Answer capsule: Kaiser treats a drug-list question and a weight-loss-benefit question as two separate questions. The formulary asks whether a product is on the plan's list. Your Evidence of Coverage or Benefit Booklet says whether your plan bought weight-loss drugs at all. A formulary exception does not create a benefit that the plan excludes.

Here's what that means in plain terms.

A formulary problem means the drug category exists in your plan, but your plan prefers a different product. Your doctor asks for an exception. Sometimes you win.

A benefit problem means your plan never bought weight-loss drugs in the first place. No amount of doctor paperwork creates a benefit that isn't there. Different problem. Different fix. Different department.

Kaiser Foundation Health Plan of Washington says this out loud in its 2026 individual, family, and small-employer drug list. Near the front, it says most plans exclude a short list that includes experimental drugs, over-the-counter drugs, drugs for expected illnesses while traveling, cosmetic drugs, and drugs for weight loss.

Read that list again. Weight-loss drugs are grouped with cosmetic products and vacation medicine. That's not a doctor's decision about you. That's a purchasing decision somebody made when they bought the plan.

And here's the part that proves it: that same Washington document lists Zepbound at Tier 3. The drug is on the list. The document also says most plans don't buy the category. Both statements sit in one PDF.

That is not Kaiser being sneaky. It's how these Kaiser documents work. A drug list tells you where a product sits if your benefit allows it. Your benefit document says whether the category is covered at all. You need both.

If you take one thing from this page, take this: before you fight over a drug, find out whether you're fighting a list problem or a benefit problem. They can look identical on a denial letter. They are not the same.

How we label every finding—and why the label matters

Answer capsule: We use seven status labels instead of a yes-or-no, because Kaiser documents genuinely say seven different things. The most important distinction is between "not found in the document we read" and "excluded"—an absence in one plan's drug list is not proof that every plan in that region says no.

Most sites give you a yes or a no. That's the reason four different pages will give you four different answers. We label what the document actually says:

Three quick definitions, since these letters are all over Kaiser's paperwork:

• PA (prior authorization) — your doctor has to ask permission before the plan will pay.
• QL (quantity limit) — the plan caps how much you can get in a set period.
• ST (step therapy) — you have to try something else first.

One more rule we follow: tiers don't compare across regions. Tier 2 in California and Tier 2 in Washington are set by different plans with different cost structures. A lower tier number in one market doesn't mean cheaper than a higher number in another.

The right GLP-1 path isn't the same for everyone—it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred form, and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized path with source-checked pricing before you choose.

What GLP-1 does Kaiser cover by plan and region?

Answer capsule: Kaiser publishes different drug lists for each market and plan type. The same drug can sit at a different tier—or not appear at all—depending on the exact document. The table below shows what each named document says, the date it took effect, and what still has to be confirmed before you treat it as coverage.

This is the work that matters. We opened the documents. Here's every row, with the exact plan scope and date on it.

The RX Index Kaiser GLP-1 Coverage Status Grid—verified August 6, 2026

Four things jump out of that grid.

1. California is the surprise—but only for the exact Commercial HMO plans named. If you've read older Kaiser guides, you may believe Wegovy is off the table in California. The current Northern and Southern California Commercial HMO lists—both effective August 4, 2026—put Wegovy injection and Wegovy HD at Tier 2. It doesn't guarantee your specific plan pays, but "Kaiser California never lists Wegovy" is not what the current Commercial HMO documents say.

2. Georgia is the widest representative formulary we found. Five named GLP-1 products sit on one five-tier list, including Wegovy and Zepbound. All are Tier 5 with prior approval and quantity limits, so it's not cheap and it's not automatic. But they're there. Georgia publishes other formularies too, so first make sure this five-tier document is yours.

3. Washington is the clearest proof of the two-questions problem. Zepbound sits at Tier 3 on the exact individual/family and small-group list. The same document says most plans exclude drugs for weight loss. Listed and covered are different words for a reason.

4. Northwest has a formulary that hasn't started yet. A Kaiser Northwest Commercial formulary dated September 17, 2026, lists Ozempic and Wegovy products with prior approval. As of August 6, it isn't the current document. The effective date is 42 days after this review date. If you see two files, the effective date tells you which one governs today.

Two things this grid can't tell you. It can't tell you whether your employer bought the weight-loss benefit, and it can't tell you your copay. Those live in your own plan documents. Every row above is an exact representative document—the starting point, not the finish line.

Kaiser GLP-1 Coverage Checker: run these five checks

Five checks. No email. No account.

1. Which Kaiser region are you in?
2. Where did the plan come from—your job, the individual market, Medicaid, Medicare, or a federal/postal job?
3. What is the exact plan name on your card, portal, EOC, or Benefit Booklet?
4. Which medication and form—such as Ozempic injection, Wegovy tablet, Wegovy HD, or Zepbound KwikPen?
5. What was it prescribed for?

You should end with: the right status label, the exact Kaiser document and effective date, whether prior approval or quantity limits apply, what the finding means, what it does not mean, the official source, and the exact words to use with Member Services.

This is a source-guided status check, not a coverage guarantee or medical advice. Your plan document and Kaiser's decision control the outcome.

→ Run the five checks in the exact-plan walkthrough

Which Kaiser are you? The five doors

Answer capsule: Kaiser's answer to a GLP-1 question is decided first by where your plan came from—a job, the individual market, Medicaid, Medicare, or federal service. These five sources follow different rulebooks. State or federal rules can control the answer before Kaiser's own formulary does.

Kaiser posts separate files for individual plans, small employers, large employers, self-funded plans, Medicare, FEHB, PSHB, Marketplace plans, and other plan designs. "Kaiser's formulary" isn't one thing. Find your door.

If your plan came from your job

Your employer picked whether weight-loss drugs are in the benefit. Kaiser built the plan; your employer chose the options.

Call HR and ask this exact question: "Does our Kaiser plan include coverage for weight-loss medications? Not diabetes drugs—weight-loss drugs, like Wegovy or Zepbound." Draw that line clearly or you can get a confident wrong answer, because "we cover GLP-1s" may only mean a diabetes path.

Open enrollment is the main window where you can change this answer. Special enrollment rights can also apply after certain life events. If your employer offers more than one plan, the drug list and the weight-loss benefit are real deciding factors and almost nobody looks at both.

If you bought your Kaiser plan yourself

Use the individual, family, or Marketplace document for your exact plan—not a Commercial HMO list just because it is in your state. Open the right drug list, search for your drug, and then open your Evidence of Coverage and search the word "weight."

One thing worth knowing before you give up: the exact Washington individual/family and small-group list places Qsymia and generic phentermine-topiramate at Tier 3 with prior approval. That is a formulary finding, not a promise that your weight-loss benefit pays. It may not be the medicine you wanted. It is still worth asking about if your benefit allows weight-loss drugs.

If you have Kaiser through Medicaid

Kaiser may not be the one deciding. In California, the state runs the pharmacy benefit for Medi-Cal members, including Kaiser members, through Medi-Cal Rx.

On January 1, 2026, Medi-Cal stopped covering GLP-1 drugs when used only for weight loss or weight-loss-related indications. Previously approved weight-loss PAs ended December 31, 2025. But the product-specific next step now matters:

### A temporary Wegovy rule is still active in August 2026 Medi-Cal Rx says members younger than 21 can receive a temporary Reject 80 continuation override through September 30, 2026 when the Wegovy claim is dated April 1 or later and the member has a paid Wegovy claim dated January 1 or later. Starting October 1, an active PA or the required MASH diagnosis code is needed. For members 21 or older, Wegovy PAs submitted from January 1 through March 31, 2026, are honored through their already-approved authorization period. Other claim rules still apply.

### The 10-day rule almost nobody knows If you were taking a GLP-1 on or before January 1, 2026, and you request a State Hearing within 10 days of the Notice of Action, California's member notice says continued medication can apply while the dispute is pending—but only until the earliest of the existing authorization's end date, the hearing decision, or withdrawal of the hearing. You generally get 90 days to request the hearing. You get 10 days to ask for continued medication under that notice. Those are different deadlines, and the short one is the one that matters. This is free. It's in California's own member notice. And it's one of the most valuable facts on this page if you're a Medi-Cal member who just got cut off.

California was not the only state that changed adult obesity coverage in 2026. KFF reported that California, New Hampshire, Pennsylvania, and South Carolina ended fee-for-service Medicaid coverage for obesity GLP-1s on January 1. If you're on Oregon Health Plan or Washington Apple Health through Kaiser, check your state's current list directly. We did not audit those state programs for this page.

If you have Kaiser through Medicare

Federal Part D rules exclude drugs when they are used only for weight loss. That's a federal rule, not Kaiser being strict. Kaiser publishes a separate Medicare Part D formulary, and your exact plan documents govern.

What can still run through Part D: type 2 diabetes and other Part D-coverable uses, including certain FDA-approved paths for cardiovascular risk reduction, obstructive sleep apnea, and MASH, depending on the product and your diagnosis.

There's also a separate federal program. CMS launched the Medicare GLP-1 Bridge on July 1, 2026, and currently schedules it through December 31, 2027. Eligible members pay a $50 copay per monthly fill. The Bridge sits outside normal Part D payment, so the $50 does not count toward the Part D deductible or true out-of-pocket total.

The exact product form matters. As of August 6, 2026, CMS lists:

• Foundayo tablets
• Wegovy injections and tablets, including the listed Wegovy formulations
• Zepbound KwikPen only—not the single-dose pen or vial

A prescriber must send a prior-authorization request. CMS gives three adult entry routes:

The Bridge is for eligible weight-management use. If your prescription is for a Part D-coverable indication such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, qualifying MASH, or cardiovascular risk reduction, CMS says the request belongs with the Part D plan instead.

There is one eligibility trap worth knowing before you apply: if Medicare Part D already paid for any GLP-1 prescription for you during 2026, CMS says you are not eligible for the Bridge in 2026. That includes a Part D fill paid through supplemental weight-management coverage.

We'll say the quiet part: if you qualify, $50 for the covered medicine beats every complete manufacturer-direct medication price in the comparison table later on this page. Ro's $39 first-month number is only a membership fee; medication is separate. Read our Medicare GLP-1 Bridge guide before you read the cash-pay section.

If you have Kaiser through a federal or postal job

You have one of the clearest published weight-loss-drug paths we found in the Kaiser system, and many federal employees don't know it.

Kaiser's own 2026 FEHB materials say it offers GLP-1 drugs and oral anti-obesity medications at 50% coinsurance of the plan allowance. The 2026 FEHB and PSHB brochures we checked also describe 50% cost sharing for weight-management drugs. Prior approval applies, and Kaiser says the guidelines can vary by market and brochure.

Kaiser's published requirements for these plans may include:

• Enrolling in a lifestyle and guided behavioral program
• A baseline BMI of 27 or higher with a weight-related condition
• Documented intolerance to—or failure to lose and keep off at least 5% of body weight after a 3-month trial of—other weight-management medications

That last line is the one nobody warns you about. You may need three months on a different weight-loss medication before the GLP-1 conversation even starts. That's a full quarter. Knowing it today instead of in March is worth real time.

Once you're approved, Kaiser's all-regions FEHB document describes an in-office exam with a weigh-in every four weeks, an attestation that you're on a reduced-calorie diet and moving more, an initial approval of 3 to 6 months, and a reassessment at the 3-month mark. Kaiser's materials also describe programs with 26 or more contact hours over 3 to 12 months. Your market brochure and criteria control the final rule.

Does Kaiser cover Wegovy?

Answer capsule: Sometimes, and it varies more than any other GLP-1 we tracked. The Northern and Southern California Commercial HMO formularies effective August 4, 2026, list Wegovy injection and Wegovy HD at Tier 2. Georgia's Five-Tier formulary lists Wegovy at Tier 5 with PA and QL. Mid-Atlantic and Northwest publish separate approval criteria. Wegovy was not found in the Colorado Commercial HMO, Hawaii Marketplace, or Washington individual/small-group documents we reviewed.

Where Wegovy showed up:

• Northern California and Southern California — Wegovy injection and Wegovy HD at Tier 2 on the exact Commercial HMO lists effective August 4, 2026. These documents are not the California Marketplace formulary.
• Georgia — Tier 5, with prior approval and quantity limits, on the exact Five-Tier Benefit formulary.
• Mid-Atlantic — approval criteria effective August 4, 2026, including separate treatment paths and product-form preferences.
• Northwest — current criteria for Wegovy injection and Wegovy tablets. Weight-management access is explicitly tied to whether your plan includes the benefit. A future Commercial formulary effective September 17, 2026, lists Wegovy products with PA.

Where it wasn't found: the Colorado Commercial HMO, Hawaii Marketplace, and Washington individual/family and small-group documents we read.

Be careful with the California finding. It says the exact Commercial HMO plan lists Wegovy at Tier 2. It does not say every California Kaiser member has a weight-management benefit, and it does not say Wegovy is covered for every treatment reason. Your Evidence of Coverage and any applicable review rules still decide.

If a page tells you flatly that Kaiser California doesn't cover Wegovy, check the plan type and the date on what it read.

Does Kaiser cover Zepbound?

Answer capsule: Zepbound appears on the Georgia Five-Tier and Washington individual/small-group formularies we reviewed and has published approval criteria in Kaiser Mid-Atlantic and Kaiser Northwest. But Northwest's own documents say weight-management coverage depends on whether your plan includes that benefit—so Zepbound can have a criteria path and still not be payable for you.

Where Zepbound showed up:

• Georgia — Tier 5, prior approval and quantity limits, on the Five-Tier Benefit formulary.
• Washington — Tier 3, prior approval and quantity limits, on the individual/family and small-group list effective August 1, 2026.
• Mid-Atlantic — approval criteria effective August 4, 2026; the form identifies Zepbound KwikPen as the preferred tirzepatide product for the paths it covers.
• Northwest — approval criteria effective June 18, 2026; weight-management coverage is benefit-dependent.

Where it wasn't found: the Northern California Commercial HMO, Southern California Commercial HMO, Colorado Commercial HMO, and Hawaii Marketplace documents we read.

Washington is the row to study. Zepbound is on the list at Tier 3. The same document says most plans exclude weight-loss drugs. That is the two-questions problem in one PDF, and it's why "is it on the formulary" is the wrong first question.

Zepbound and Mounjaro are not interchangeable coverage questions. Both contain tirzepatide. They have different FDA-approved uses, forms, and Kaiser criteria. Don't assume one answer transfers to the other.

Does Kaiser cover Ozempic?

Answer capsule: Ozempic appeared in all eight exact 2026 plan documents or criteria sets we reviewed. It sits at Tier 2 in the Northern and Southern California Commercial HMO formularies and the Washington individual/small-group formulary, Tier 3 with PA in the Colorado Commercial HMO formulary, Tier 5 with PA and QL in Georgia's Five-Tier formulary, and Tier 3 in the Hawaii Marketplace formulary. Mid-Atlantic and Northwest publish product-specific criteria. Its presence does not prove coverage for your diagnosis.

Ozempic is FDA-approved for type 2 diabetes and certain related risk-reduction uses in the approved label. It is not FDA-approved as a chronic weight-management product—Wegovy is the semaglutide brand with weight-management indications.

But "Ozempic for weight loss always rejects" is too simple. Kaiser Northwest's own 2026 Ozempic criteria include several treatment paths, including a benefit-dependent chronic-weight-management path and other non-diabetes uses. The honest question is not only what FDA approved. It is what your exact Kaiser plan and current criteria allow for the diagnosis on your prescription.

One finding worth knowing if you're in Washington and have a covered use: Ozempic sits at Tier 2 while Mounjaro sits at Tier 3 on the same exact list. Same broad class, different tier. If both are clinically reasonable for your situation, that difference is worth raising with your doctor.

Ask Kaiser this: "Is Ozempic covered under my exact plan for the diagnosis on my prescription, and what prior authorization, step therapy, quantity limit, benefit exclusion, prescriber, or pharmacy rule applies?"

Does Kaiser cover Mounjaro?

Answer capsule: Mounjaro appears on Georgia's Five-Tier formulary at Tier 5 and the Washington individual/small-group formulary at Tier 3, both with prior approval and quantity limits. Kaiser Mid-Atlantic and Northwest publish approval criteria. It was not found in the Northern California Commercial HMO, Southern California Commercial HMO, Colorado Commercial HMO, or Hawaii Marketplace documents we reviewed.

Mounjaro is the tirzepatide product approved for type 2 diabetes. Zepbound is the tirzepatide product with weight-management and sleep-apnea indications. Kaiser handles the products, forms, diagnoses, and benefit paths separately, and so should you when you're asking questions.

Kaiser Northwest's Mounjaro criteria even include a benefit-dependent chronic-weight-management path. That is another reason not to turn an FDA label difference into a blanket insurance answer.

"Not found" is not "excluded." It means the exact product name wasn't in the specific document we searched. Ask your plan whether a non-formulary exception exists, whether a different plan document applies to you, or whether there's a separate criteria form.

Does Kaiser cover Wegovy tablets, Foundayo, Rybelsus, Saxenda, Trulicity, or liraglutide?

Answer capsule: These are also plan- and form-specific. A liraglutide product or criteria path appeared in seven of the eight exact documents or criteria sets we reviewed. Rybelsus appears in the Washington formulary and Mid-Atlantic criteria. Wegovy tablets have current criteria in Mid-Atlantic and Northwest. Foundayo has a Mid-Atlantic approval form effective August 4, 2026. Saxenda appears in Georgia's Five-Tier formulary. Trulicity appears in Georgia and Washington.

Liraglutide is the quiet story here. Generic liraglutide showed up at Tier 1 in the Northern California Commercial HMO, Southern California Commercial HMO, and Washington individual/small-group lists. It is Tier 2 with PA in the Colorado Commercial HMO list, Tier 2 in the Hawaii Marketplace list, and appears with controls in Georgia and with a Mid-Atlantic criteria form.

Straight talk about the tradeoff: liraglutide is a daily injection, not weekly. The exact product and diagnosis matter. A Tier 1 generic liraglutide listing does not automatically mean your plan pays for obesity treatment.

But here's the editorial judgment we'll make out loud, based on the tiers above: a lower-tier product your plan actually covers can beat a higher-tier product you spend months appealing. If cost is your binding constraint, ask Kaiser which product and indication your exact benefit allows.

Three more things:

Form matters. Ozempic injection, Ozempic tablets, Rybelsus tablets, Wegovy injection, Wegovy HD, Wegovy tablets, Zepbound KwikPen, and single-dose Zepbound forms are separate coverage questions. Don't collapse them into one drug name.

New products can lag. A new product may not appear in every regional formulary right away. That can be a publication or review lag, but it is not proof of coverage. Ask whether a new-product review or non-formulary process applies.

Foundayo is not a typo. FDA approved oral orforglipron under the brand name Foundayo in April 2026. Mid-Atlantic published a Foundayo PA form effective August 4, 2026, and CMS includes Foundayo tablets in the Medicare GLP-1 Bridge for eligible members.

What BMI does Kaiser require for a GLP-1?

Answer capsule: There is no one Kaiser BMI rule. Kaiser Northwest's current Wegovy and Zepbound weight-management criteria use BMI 30 or higher, or BMI 27 or higher with at least one listed condition, plus other requirements and a weight-loss-medication benefit. Kaiser's 2026 federal and postal materials publish a separate path that may start at BMI 27 or higher with a weight-related condition. Zepbound for sleep apnea has a different Northwest path.

We went to the primary Kaiser files instead of copying one national number:

We're not calling one number "the Kaiser cutoff" because the files do not support that. The threshold changes by region, plan, drug, form, age, and reason for treatment.

And here's the thing that actually matters: if your plan doesn't include a weight-loss drug benefit, your BMI is irrelevant to that benefit. The category isn't covered at any number. Sort out the benefit question first. The BMI question only matters after that.

What does Kaiser's prior approval actually ask for?

Answer capsule: Kaiser publishes drug-by-drug approval criteria as public documents in several regions, including Northwest and Mid-Atlantic, covering Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo, liraglutide, and oral semaglutide products. Most members never learn these exist, which means most people walk into the request without knowing what it's judged against.

You can read the test before you take it.

Kaiser Northwest posts approval criteria as individual PDFs. Kaiser Mid-Atlantic publishes product-family forms—a set took effect August 4, 2026—covering semaglutide, tirzepatide, Foundayo, and liraglutide products.

That's a genuine advantage and almost nobody uses it. Print the criteria for your exact drug and form. Bring it to your appointment. Go through it line by line with your doctor before anything gets submitted.

What to gather before the request:

• Your exact plan name, off your ID card or benefits portal
• The medication and exact form—injection, tablet, pen, or KwikPen
• The diagnosis on the prescription
• Any prior treatment history the criteria document asks for
• Current clinical records, including current weight or BMI when requested
• The denial letter, if you already have one
• The exact criteria form for your region

What we won't do here: publish a universal BMI cutoff, a required number of failed medications, a required program length, or one approval timeline. Those change by region, plan, product, form, age, and reason. Any page that hands you a single national checklist is guessing.

How to check your exact Kaiser plan in seven steps

Answer capsule: Match five facts before trusting any coverage answer: your region, where the plan came from, your exact plan name, your medication and form, and the reason it was prescribed. Then check two documents, not one—the formulary and your Evidence of Coverage or Benefit Booklet—because each one leaves out the part the other answers.

Step 1—Find your exact plan name. It's on your member ID card, your enrollment portal, your Evidence of Coverage, your Benefit Booklet, or your employer's benefits site.

Step 2—Name the source of the plan. Is it from your job, bought directly, Marketplace, Medicaid, Medicare, FEHB, or PSHB? That sends you to the right rulebook.

Step 3—Pick the right region and document. Washington and Northwest are separate document systems even though they share a border. California Commercial HMO and California Marketplace are separate lists. Getting this wrong means reading the wrong file.

Step 4—Search the exact product and form. Search the brand name and the generic ingredient. Injection, tablet, HD pen, KwikPen, single-dose pen, and vial can have different answers.

Step 5—Read the small letters. PA, QL, ST, days-supply rules, specialty-pharmacy notes, and the effective date at the bottom or top of the file.

Step 6—Open your Evidence of Coverage or Benefit Booklet. This is the step people skip and it's the one that answers the benefit question. Search these words: weight loss, obesity, anti-obesity, weight management, prescription drug exclusions, non-formulary exception.

Step 7—Call with a script. Read this word for word:

"Please confirm whether [medication and exact form] is covered under my exact plan for [the diagnosis on my prescription]. Is it formulary-listed, subject to prior authorization, available through a non-formulary exception, or excluded by my benefit? What prior authorization, step therapy, quantity limit, days-supply, prescriber, or pharmacy requirements apply? Please give me the exact document or form name, its effective date, and a reference number for this call."

Write down the date, representative's name, call reference number, plan document, effective date, form name, and any authorization or denial number. If you end up appealing, this is your foundation.

Free. No email. Copy the script and take it with you.

What if Kaiser says no?

Answer capsule: A denial is not one problem—it's five, and they need different responses. Before you file anything, read the denial notice and identify whether the issue was missing information, an unmet clinical criterion, non-formulary status, a preferred alternative, or a benefit exclusion.

Your appeal path depends on your door:

Some California managed-care members have an extra path. The California Department of Managed Health Care runs a free Independent Medical Review where outside doctors can review certain denials. Members generally start with the plan's grievance process, though urgent rules can shorten the wait. Check whether DMHC regulates your exact plan before relying on this route.

One fact can change the whole route: a separate covered indication. Wegovy has cardiovascular and MASH paths in current public rules. Zepbound has an obstructive-sleep-apnea path. Those requests are not the same as a weight-loss-only request. If you already have one of these diagnoses, make sure the accurate diagnosis is in the request. We are talking about conditions you already have—never about seeking or adding a diagnosis you don't.

→ Build my next-step plan with Find My GLP-1 Path

What if your Kaiser plan won't pay?

Answer capsule: There is an order to the options, and the lowest-cost one is often not the telehealth one. Use a valid Kaiser benefit first. Use the Medicare GLP-1 Bridge next if you qualify. Then compare manufacturer-direct cash prices. Use telehealth when you need the clinical service and understand the membership fee.

We're going to rank these honestly, which means putting two options ahead of the ones we can get paid for.

If you're in row 1 or row 2, stop reading this section and work that path first. We'd rather lose the click than send you somewhere worse.

Cash-pay prices we checked on August 6, 2026

These are provider- or manufacturer-stated prices, not a promise that you qualify or that the price will still be live when you click. Recheck the current terms before paying.

If you're considering Ro, here's the honest version

Ro says it can check insurance, submit prior-authorization paperwork, communicate with the insurer, and appeal some denials. So the old claim that "Ro cannot file a prior authorization" is not accurate.

But don't pay Ro just to answer a Kaiser question you can answer inside Kaiser for free. Kaiser plans often have plan-provider and plan-pharmacy rules, and we did not find a public Ro promise that it can complete every Kaiser closed-system step from prescription through fill. If your Kaiser benefit works, start with your Kaiser doctor and Kaiser pharmacy.

Ro currently offers $39 for the first month, then as low as $74 per month with an annual plan paid upfront, or $149 per month on the monthly plan. Medication cost is separate from the membership. Ro offers FDA-approved options, including products such as Zepbound and Foundayo, and says its insurance concierge can check coverage and handle PA paperwork for supported products.

The tradeoff, stated plainly: you're paying a membership fee on top of the medication. That can make sense when you want ongoing prescribing, support, and cash-pay access. It makes less sense when Kaiser will already cover the care inside your plan.

Does that sound like your situation? → Read our current Ro pricing and insurance guide

Want to choose the clinician inside a different ongoing program? → Compare Sesame Care's current weight-loss program

Why we're not sending you to compounded semaglutide here

We did not find a compounded-semaglutide coverage path in the Kaiser plan documents and criteria we reviewed. Compounded drugs are not FDA-approved, and FDA does not review them before marketing for safety, effectiveness, and quality the way it reviews approved drugs. They should never be described as the same product as an FDA-approved drug.

This page is about what Kaiser and related public programs cover. Compounded products aren't part of the verified answer we found. If that's a path you want to research, it belongs on a different page with different disclosures.

What changed for Kaiser members in 2026?

Answer capsule: Three changes reshaped the page. Medi-Cal ended coverage for GLP-1 drugs used only for weight loss on January 1, 2026, while keeping separate paths for some non-weight uses. California AB 575 died and created no obesity-drug mandate. New products and forms—including Foundayo, Wegovy HD, and oral semaglutide products—now appear in current Kaiser or federal documents.

California's proposed coverage mandate died

This matters in California, where Kaiser publishes separate Northern and Southern California plan documents.

AB 575, the Obesity Prevention Treatment Parity Act, would have required covered California health plans and insurers to cover at least one FDA-approved GLP-1 receptor agonist for the treatment or prevention of obesity, plus intensive behavioral therapy. It would have barred prior authorization and rules stricter than the FDA-approved indications for policies issued, amended, or renewed on or after January 1, 2026.

The bill died on January 31, 2026. On February 2, it was filed with the Chief Clerk under Joint Rule 56.

In plain terms: AB 575 did not create a California coverage mandate. For California Kaiser members, the current plan, EOC, formulary, and criteria still control.

The Medicaid change

Medi-Cal stopped covering GLP-1 drugs for weight-loss-only and weight-loss-related uses on January 1, 2026. But "all GLP-1 coverage ended" is wrong. Current Medi-Cal rules keep product-specific routes for type 2 diabetes and other non-weight indications, including Wegovy for MASH with the required diagnosis code, PA review for Wegovy cardiovascular use, and PA review for Zepbound in obstructive sleep apnea. Medi-Cal Rx also has a temporary Wegovy continuation override through September 30, 2026, for qualifying members under 21, while certain adult prior authorizations submitted from January 1 through March 31 remain valid through their approved period.

New products and forms changed the search

• FDA approved Foundayo, an oral orforglipron product, on April 1, 2026.
• FDA approved Wegovy HD in March 2026.
• Kaiser documents now separate Wegovy injection, Wegovy HD, Wegovy tablets, Ozempic injection, Ozempic tablets, Rybelsus, Zepbound KwikPen, and other tirzepatide forms.
• Mid-Atlantic published Foundayo, semaglutide, tirzepatide, and liraglutide forms effective August 4, 2026.
• CMS includes Foundayo tablets, Wegovy injections/tablets, and Zepbound KwikPen in the Medicare GLP-1 Bridge for eligible members.

What we're watching

Kaiser can update formularies during the year. The California Commercial HMO documents say they are updated monthly. Kaiser Northwest's next Commercial formulary takes effect September 17, 2026. New products, forms, criteria, and plan documents can change the answer before January.

That's why the date at the top of this page moves after a real recheck.

What Kaiser members are actually asking

You're not the only one untangling this.

Public discussions among Kaiser members circle the same questions over and over: will the weight-loss benefit continue next year, can a particular Kaiser program prescribe this, what documentation does the doctor actually need, was this denial the plan or the paperwork, and what happens if I just pay cash.

Here is the proof source for each question:

Those questions shaped how we organized this page. But we'll be direct about something: we don't publish provider testimonials on insurance pages. Another member's experience can't tell you what your plan covers, and dressing up an anecdote as evidence would be the opposite of useful here. The documents are the proof. That's what we've given you.

What we actually verified

And what we did not verify—because you deserve to know the edges:

• Your specific plan. Employer benefits, riders, EOCs, and Benefit Booklets are member- or group-specific. We read the exact representative documents named above.
• Your copay. Deductibles, tiers, coinsurance, and claim handling are member-specific.
• Whether an appeal will succeed. Nobody can promise that.
• Every Kaiser plan in every market. We read eight representative plan documents or criteria sets, plus the public-program and price sources named above.
• Oregon Medicaid or Washington Medicaid coverage. We did not audit those state programs for this page.

We're telling you this because a page claiming to have read every Kaiser plan in America hasn't.

Frequently asked questions

Does Kaiser cover Ozempic for weight loss? It depends on the exact plan and criteria. Ozempic is not FDA-approved as a chronic weight-management product, but Kaiser Northwest's 2026 criteria include a benefit-dependent chronic-weight-management path. Ask whether your exact plan covers Ozempic for the real diagnosis on the prescription.

Does Kaiser cover Wegovy in California? The Northern and Southern California Commercial HMO formularies effective August 4, 2026, list Wegovy injection and Wegovy HD at Tier 2. That applies to those exact formularies, not every California plan. Your EOC and any applicable review rules still decide.

Does being on the Kaiser formulary mean it's covered? No. A formulary tells you what a named drug list contains. Your benefit tells you whether the category is covered at all, and approval criteria decide the individual request. Kaiser's exact Washington document lists Zepbound at Tier 3 and separately says most plans exclude weight-loss drugs.

What's the difference between a formulary denial and a benefit exclusion? A formulary denial means the product or form is not on the list or is not preferred—an exception request may work. A benefit exclusion means your plan doesn't cover the category. More paperwork won't create a benefit that was never purchased.

Can my employer plan have different Kaiser coverage than my neighbor's? Yes. Employers can choose different pharmacy and weight-management benefits. Two members in the same city can get opposite answers.

Does Kaiser cover compounded semaglutide? We found no compounded-semaglutide coverage path in the Kaiser documents and criteria we reviewed. Compounded drugs are not FDA-approved, and they must not be described as the same product as FDA-approved semaglutide.

Does Kaiser Medicare cover GLP-1 medications? Kaiser publishes a separate Medicare Part D formulary. Part D excludes drugs used only for weight loss, but certain other uses can be covered. Eligible Medicare members using named products and forms for weight management may qualify for the separate CMS Medicare GLP-1 Bridge at a $50 monthly copay.

Which drugs are in the Medicare GLP-1 Bridge? CMS currently lists Foundayo tablets, Wegovy injections and tablets, and Zepbound KwikPen. Zepbound single-dose pens and vials are not included as of August 6, 2026.

Can I use an outside telehealth service and still use my Kaiser benefit? Sometimes the network rules make that hard. Kaiser plans can require plan or affiliated prescribers and plan or network pharmacies. An outside service may be useful for cash pay, but do not assume it can unlock your Kaiser benefit. Check your exact prescriber and pharmacy rules first.

What do PA, QL and ST mean on a Kaiser drug list? PA is prior authorization—your doctor asks permission first. QL is a quantity limit. ST is step therapy—try something else first. They mark controls, not automatic denials.

Can Kaiser prescribe a medication my plan won't pay for? Prescribing and paying are separate decisions. Your clinician decides what's medically appropriate; your plan decides what the pharmacy benefit covers. Ask both questions.

How do I find my Kaiser formulary? Go to the Kaiser drug-formulary page for your region, choose your exact plan type, and check the effective date before you rely on the file. Then check your EOC or Benefit Booklet for exclusions.

Still not sure which GLP-1 program is right for you?

Take the free Find My GLP-1 Path quiz →

It takes about two minutes. You'll get a personalized treatment path with source-checked pricing—not a list of ads.

Sources

Kaiser regional formularies and criteria

• Northern California drug-formulary page
• Northern California 2026 Commercial HMO formulary
• Southern California drug-formulary page
• Southern California 2026 Commercial HMO formulary
• Colorado 2026 Commercial HMO formulary
• Georgia 2026 Five-Tier Benefit formulary
• Hawaii Marketplace formulary
• Mid-Atlantic drug-formulary and prior-authorization page
• Mid-Atlantic semaglutide PA form
• Mid-Atlantic tirzepatide PA form
• Mid-Atlantic Foundayo PA form
• Mid-Atlantic liraglutide PA form
• Northwest Wegovy injection criteria
• Northwest Wegovy tablet criteria
• Northwest Zepbound criteria
• Northwest Ozempic criteria
• Northwest Mounjaro criteria
• Northwest Commercial formulary effective September 17, 2026
• Washington individual/family and small-employer formulary
• Kaiser Permanente 2026 Medicare Part D Comprehensive Formulary

Public-program, regulator, and legislative sources

• CMS Medicare GLP-1 Bridge
• CMS Medicare GLP-1 Bridge information for Part D plans
• CMS Medicare GLP-1 Bridge prior-authorization form
• Medi-Cal Rx member notice: Changes to GLP-1 Drug Coverage
• Medi-Cal Rx GLP-1 Coverage Considerations
• Medi-Cal Rx temporary Wegovy continuation override
• Medi-Cal Rx Contract Drugs List
• Kaiser 2026 FEHB Weight Management Programs and GLP-1 Requirements
• California AB 575 bill history
• California AB 575 bill text
• KFF: Medicaid Coverage of and Spending on GLP-1s
• California Department of Managed Health Care Independent Medical Review
• FDA: Foundayo approval
• FDA: Wegovy HD approval
• FDA: Wegovy approval for MASH
• FDA: Zepbound approval for obstructive sleep apnea
• FDA: Compounded drugs are not FDA-approved

Price sources checked August 6, 2026

• Ro Body pricing
• Ro insurance support
• Success by Sesame
• LillyDirect Zepbound
• LillyDirect Foundayo
• NovoCare Pharmacy

Disclaimer

This page is independent research about insurance coverage. It is not medical advice, and it is not a guarantee of coverage. Coverage decisions belong to your plan; clinical decisions belong to you and your clinician. Drug names are trademarks of their respective owners. The RX Index is not affiliated with, endorsed by, or sponsored by Kaiser Permanente or any pharmaceutical manufacturer.